Program
desloratadine
Also written as “Desloratadine”, “Desloratadine 5 mg” and “Desloratadine 5 mg (Clarinex)”.
Its studies are mostly in Rhinitis, Allergic, Seasonal · Rhinitis, Allergic · Urticaria · Hypersensitivity · Chronic Urticaria, led by 6 companies.
Drug pageDesloratadine: every studyMany companies study it; this page follows only the 39 they lead. All 55 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Organonits history only | 270 open or running | phase 4since Apr 4, 2006 | Apr 4, 2006 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 60 open or running | phase 1since Mar 11, 2011 | Mar 11, 2011 | none ahead |
| EMS | 30 open or running | phase 3since Feb 6, 2012 | Feb 6, 2012 | none ahead |
| Ache Laboratorios Farmaceuticosits history only | 10 open or running | phase 3since Mar 8, 2016 | Mar 8, 2016 | none ahead |
| Eurofarma Laboratoriosits history only | 10 open or running | phase 3since Dec 13, 2021 | Dec 13, 2021 | none ahead |
| Laboratorios Silanes S.A. de C.V.its history only | 10 open or running | phase 3since Apr 1, 2025 | Apr 1, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of EMS only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 6, 2012First studies: 2 phase 3 studiesFirst studyNCT01529242, NCT01529229
- Oct 31, 2012Phase 3 study in Rhinitis, AllergicNCT01720485 · 234 enrolled · Brazil
TargetBeta
“Histamine H1 receptor antagonist”ChEMBL 37, by rule
Other programs on HRH1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| fexofenadinerule | Sanofi | phase 4 | 38 |
| bilastinerule | faes-farma-s-a | phase 4 | 19 |
| Diphenhydraminerule | Johnson & Johnson | phase 4 | 16 |
Studies
All 3 EMS leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01720485Rhinitis, Allergic · Brazil | 3 | UNKNOWN | Dec 2013 | 234 |
| NCT01529242Cutaneous Hypersensitivity · Brazil | 3 | Terminated | Aug 2016 | 17 |
| NCT01529229Rhinitis, Allergic | 3 | Completed | Oct 2014 | 210 |
How it is read
Names in the registry
- “Desloratadine”, 12 entries
- “desloratadine”, 11 entries
- “Desloratadine 5 mg”, 3 entries
- “Desloratadine 5 mg (Clarinex)”, 3 entries
- “Desloratadine + Prednisolone”, 3 entries
Conditions, from the studies’ own filings
- Rhinitis, Allergic, Seasonal, 10 studies
- Rhinitis, Allergic, 6 studies
- Urticaria, 5 studies
- Hypersensitivity, 3 studies
- Chronic Urticaria, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.